What’s new in checkpoint inhibition? LAG-3/PD-1 bispecifics, ADC combos, and more
About this episode
The episode discusses updates on checkpoint inhibition and novel immunotherapy strategies in cancer treatment.
In this week’s VJOncology podcast, we bring you key updates on the evolving landscape of checkpoint inhibition beyond PD-1 and PD-L1 across solid tumors. Join leading experts Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Madrid, Spain, Laurence Buisseret, MD, PhD, Institute Jules Bordet, Brussels, Belgium, and Yuxiang Ma, MD, PhD, Sun Yat-Sen University Cancer Center, Guangzhou, China, as they discuss novel bispecific and bifunctional immunotherapy strategies, first-in-human and early-phase clinical data, and emerging checkpoint inhibitor–ADC combinations shaping treatment paradigms in breast cancer, urothelial carcinoma, and other advanced malignancies.
More episodes of VJOncology Podcast
- Bladder Cancer Awareness Month: subtypes, diagnostics & breakthroughs
- Beyond EGFR: navigating molecular targets and emerging therapies in advanced NSCLC
- Head and neck cancer awareness month: key trials and evolving treatment strategies
- Lung cancer highlights from the 24th BTOG annual conference
- Immuno-oncology updates from 12th Immunotherapy of Cancer Conference
- Top updates from ASCO GU 2026: latest trials in prostate, kidney, and bladder cancer
Explore listener stats, chart rankings, contacts and more on the VJOncology Podcast podcast page.